載入中
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
前收盤價
US$14.58
+US$0.36 · +2.53%
盤中時間採用ET。市場資料可能有所延遲。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
日內區間
目前US$14.58
52週區間
目前US$14.58
盤中時間採用ET。市場資料可能有所延遲。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
日內區間
目前US$14.58
52週區間
目前US$14.58
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.55億 USD | 6.05億 USD | 5.09億 USD | 5.38億 USD | 5.35億 USD |
| 銷貨成本 | 1.67億 USD | 1.37億 USD | 1.28億 USD | 1.15億 USD | 1.15億 USD |
| 毛利 | 4.88億 USD | 4.68億 USD | 3.81億 USD | 4.23億 USD | 4.2億 USD |
| 研究與開發 | 2.25億 USD | 2.1億 USD | 2.23億 USD | 2.06億 USD | 2.01億 USD |
| 銷售、一般及管理費用 | 4.18億 USD | 4.29億 USD | 3.91億 USD | 3.06億 USD | 2.63億 USD |
| 營業費用 | 6.42億 USD | 6.39億 USD | 6.15億 USD | 5.12億 USD | 4.64億 USD |
| 利息收入 | 1811.1萬 USD | 5099.7萬 USD | 4603.6萬 USD | 1579萬 USD | 109.7萬 USD |
| 利息支出 | — | 1166.3萬 USD | 490.6萬 USD | 811.3萬 USD | 883.9萬 USD |
| 折舊和攤銷 | 1465萬 USD | 1123.5萬 USD | 1096.9萬 USD | 1062.4萬 USD | 1025.1萬 USD |
| 營業利益 | −1.54億 USD | −1.7億 USD | −2.33億 USD | −8952.3萬 USD | −4433.3萬 USD |
| 淨利 | −1.36億 USD | −1.69億 USD | −2.07億 USD | −9253.4萬 USD | −5835.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6173.52萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB4464.81萬0.02%1853億 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM3994.49萬0.05%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK2557.89萬0.06%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2158.62萬0.02%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO1306.32萬0.09%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB1153.59萬0.11%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1085.12萬0.06%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
